Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Kaye, Joel, Piryatinsky, Victor, Birnberg, Tal, Hingaly, Tal, Raymond, Emanuel, Kashi, Rina, Amit-Romach, Einat, Caballero, Ignacio S., Towfic, Fadi, Ator, Mark A., Rubinstein, Efrat, Laifenfeld, Daphna, Orbach, Aric, Shinar, Doron, Marantz, Yael, Grossman, Iris, Knappertz, Volker, Hayden, Michael R., Laufer, Ralph
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2016
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5068259/
https://ncbi.nlm.nih.gov/pubmed/27671624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607843113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados